3//SEC Filing
BP Directors, LP 3
Accession 0001813311-22-000001
CIK 0001455365other
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 7:33 PM ET
Size
7.2 KB
Accession
0001813311-22-000001
Insider Transaction Report
Form 3
BP Directors, LP
Director10% Owner
Holdings
- (indirect: By Dr. Aaron Fletcher)
Stock Option (right to buy)
Exercise: $1.75Exp: 2031-02-23→ Common Stock (1,145 underlying)
Footnotes (5)
- [F1]Consists of options to purchase 1,145 shares of common stock of the Issuer, par value $0.001 per share ("Shares"), granted in consideration for Dr. Aaron Fletcher's services as a director of the Issuer. These options were granted to Dr. Fletcher on February 23, 2021, together with options to purchase 2,719 additional Shares (3,864 Shares in total).
- [F2]These options vests in four (4) equal annual installments beginning on February 1, 2022. These options were granted on February 23, 2021.
- [F3]Bios Equity Partners, LP ("Bios Equity I") is the general partner of BP Directors, LP ("Bios Directors"). Cavu Management, LP ("Cavu Management") and Bios Capital Management, LP ("Bios Management") are the general partners of Bios Equity I. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Leslie W. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Dr. Fletcher, is the general partner of Bios Management.
- [F4]Pursuant to a preexisting agreement, Dr. Fletcher is deemed to hold the reported options (covering 1,145 Shares) for the benefit of Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported options, and Bios Equity I, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors, Mr. Kreis and Dr. Fletcher (collectively, the "Bios Parties") may each be deemed the indirect beneficial owner of the reported options through his or its respective indirect interest in Bios Directors. In connection with a different event, each of the Bios Parties have filed a Form 3 covering securities of the Issuer.
- [F5]For purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, the Reporting Person disclaims beneficial ownership of any of the reported securities except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Documents
Issuer
COGNITION THERAPEUTICS INC
CIK 0001455365
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001813311
Filing Metadata
- Form type
- 3
- Filed
- Jan 31, 7:00 PM ET
- Accepted
- Feb 1, 7:33 PM ET
- Size
- 7.2 KB